Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.103 USD | +1.72% | -0.24% | -55.80% |
Financials (USD)
Sales 2024 * | 600K | Sales 2025 * | 600K | Capitalization | 7.68M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -31M | EV / Sales 2024 * | 12.8 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 12.8 x |
P/E ratio 2024 * |
-0.42
x | P/E ratio 2025 * |
-0.41
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.12% |
Latest transcript on TFF Pharmaceuticals, Inc.
1 day | +1.72% | ||
1 week | -0.24% | ||
Current month | -48.63% | ||
1 month | -52.19% | ||
3 months | -38.34% | ||
6 months | -60.61% | ||
Current year | -55.80% |
Managers | Title | Age | Since |
---|---|---|---|
Harlan Weisman
CEO | Chief Executive Officer | 71 | 18-11-30 |
Kirk Coleman
DFI | Director of Finance/CFO | 51 | 18-01-23 |
Zamaneh Mikhak
CTO | Chief Tech/Sci/R&D Officer | 59 | 23-01-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 18-11-30 | |
Brandi Roberts
BRD | Director/Board Member | 50 | 22-03-24 |
Thomas King
BRD | Director/Board Member | 69 | Dec. 12 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 3.103 | +1.72% | 2 142 |
24-04-25 | 3.05 | +1.33% | 19,364 |
24-04-24 | 3.01 | +1.35% | 12,712 |
24-04-23 | 2.97 | +15.12% | 62,771 |
24-04-22 | 2.58 | -17.04% | 47,266 |
Delayed Quote Nasdaq, April 26, 2024 at 11:03 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.80% | 7.68M | |
+2.28% | 42.59B | |
+7.68% | 40.65B | |
+48.83% | 40.57B | |
-11.96% | 26.77B | |
+8.74% | 24.81B | |
-23.73% | 18.17B | |
+28.06% | 12.05B | |
-2.72% | 11.7B | |
+7.00% | 11.1B |
- Stock Market
- Equities
- TFFP Stock